Phase II Trial of RAD001 in Refractory Colorectal Cancer

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Site Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms Rectal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Swedish Cancer Institute

Seattle, Washington, 98104, United States

About this study

Study is completed and closed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
Measurable disease
ECOG 0-2

Exclusion criteria

CNS disease
Chemotherapy or radiotherapy < 4 weeks prior
Active bleeding diathesis

Treatment and study plan

RAD001

Drug

Sponsors and collaborators

Lead sponsor

Swedish Medical Center

Other

Collaborators

Novartis

Registry information

Official study title

Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer

Important dates

Study start: 2006
Study completion: 2007
First posted: Jun 16, 2006
Registry last updated: Oct 10, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed